TICKERNERD
Menu
SGMTSGMTHealthcare · Biotechnology

SGMT Stock Forecast: Sagimet Biosciences, Inc. Price Predictions for 2026-2027

Last close, 23 Oct 2026
$9.58
−3.72% on the day

The 12 Wall Street analysts covering Sagimet Biosciences, Inc. hold a median 12-month price target of $27 — +181.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 22 Oct 2026 — in the lower half.

Market cap
$708.4M
Ticker Nerd rank
40/ 100
Median analyst target
$27
Analysts covering
12
Revenue$0.0
Operating income−$15.8M
Net income−$14.0M
Free cash flow−$11.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+19.5%
1M
−8.1%
YTD
+61.8%
1Y
+30.7%
From 52W high
−14.2%
From 52W low
+110.5%
$5
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SGMT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sagimet Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
40/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
82
Growth
72
Value
62
Quality
53
Size
48
Revisions
43
Accruals
23
Volatility
20
Issuance
17

Momentum (82): The shares have been drifting up relative to others.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SGMT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SGMT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26SGMTHigh $56Median $27Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11 Buy0 Hold1 Sell
Low $7Median $27High $56

The green dot is the last close — the median target sits +181.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
5 Oct 2026HC Wainwright & Co.ReiteratesBuy$29
2 Oct 2026GuggenheimMaintainsBuy$25 → $26
1 Oct 2026CitizensMaintainsMarket Outperform$29 → $27
1 Oct 2026OppenheimerMaintainsOutperform$33 → $38
24 Sept 2026Goldman SachsReinstatesSell$7.00
9 Sept 2026BarclaysUpgradeOverweight$8.00 → $18
9 Sept 2026BarclaysUpgradeOverweight—
9 Sept 2026Cantor FitzgeraldInitiatesOverweight$11
9 Sept 2026Cantor FitzgeraldInitiatesOverweight—
25 Aug 2026HC Wainwright & Co.ReiteratesBuy—
25 Aug 2026HC Wainwright & Co.ReiteratesBuy$29
14 Aug 2026CitizensMaintainsMarket Outperform—
14 Aug 2026CitizensMaintainsMarket Outperform$12 → $29
12 Aug 2026Canaccord GenuityMaintainsBuy—
12 Aug 2026Canaccord GenuityMaintainsBuy$49 → $56
19 May 2026CitizensMaintainsMarket Outperform$35 → $12
19 May 2026CitizensMaintainsMarket Outperform—
4 May 2026Canaccord GenuityMaintainsBuy—
29 Apr 2026GuggenheimMaintainsBuy—
11 Mar 2026HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SGMT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

SGMT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, Sagimet Biosciences, Inc. returned +30.7% against +14.3% for the S&P 500, dividends included.

SGMT vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26SGMTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SGMT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Sagimet Biosciences, Inc. (SGMT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.3×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
2.4×

Cheaper than 37% of US stocks

EV / EBITDA
−6.7×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−24.4%

Higher than 30% of US stocks

Return on assets
−16.4%

Higher than 22% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sagimet Biosciences, Inc. (SGMT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sagimet Biosciences, Inc. has a market value of $708.4M and an enterprise value of $382.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$47.1M.

  • Diluted earnings per share, trailing twelve months: $−1.28.

  • Free cash flow in the twelve months to 30 June 2026: −$41.7M.

  • Shares outstanding: 61.8M.

  • Trailing P/E: −6.3×; forward P/E: −7.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Sagimet Biosciences, Inc. employs 16 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

SGMT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SGMTSagimet Biosciences, Inc.$708.4M40
OABIOmniAb, Inc.$695.0M97
IMMXImmix Biopharma, Inc.$692.2M31
SANASana Biotechnology, Inc.$709.5M31
ANNXAnnexon, Inc.$722.3M37
GERNGeron Corp.$723.8M49
PRMEPrime Medicine, Inc.$676.5M41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sagimet Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SGMT news & analysis

Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet

Zacks Investment Research · 23 Oct 2026positive

Zacks Investment Research reported that the consensus price target for Sagimet Biosciences implies about 168.2% upside. It also noted that this metric has limited effectiveness, while upward earnings-estimate revisions may indicate near-term upside.

Why it matters — SGMT watchers may consider the price-target estimate and earnings-revision trend, alongside the source's caution about the metric.

Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne

GlobeNewsWire · 22 Oct 2026positive

Sagimet Biosciences announced that the first patient has been dosed in AURORA, its pivotal U.S. Phase 3 trial of denifanstat for moderate to severe acne in adults and adolescents aged 12 and older. The trial is designed to enroll approximately 800 U.S. patients.

Why it matters — The dosing milestone advances denifanstat’s U.S. registrational program following positive Phase 3 clinical results in China from license partner Ascletis.

Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet

Seeking Alpha · 21 Oct 2026positive

Seeking Alpha describes Sagimet’s pivot of denifanstat to acne, citing prior Phase 3 data and an ongoing, fully funded U.S. registrational trial. The article frames the trial as a test of replicating results in the U.S., rather than a drug-discovery effort.

Why it matters — SGMT watchers may note the focus on U.S. trial replication and denifanstat’s potential as an oral acne therapy.

After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)

Zacks Investment Research · 15 Oct 2026positive

Zacks Investment Research says SGMT is technically oversold after a 27.9% decline over four weeks. It cites higher earnings estimates from Wall Street analysts alongside the oversold reading as possible signs of a near-term trend reversal.

Why it matters — SGMT watchers may note the report’s combination of technical conditions and analyst estimate revisions as factors it says could signal a change in the stock’s recent trend.

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

GlobeNewsWire · 9 Oct 2026positive

Sagimet said positive 52-week results from Ascletis’ Phase 3 ASC40-304 open-label extension trial of denifanstat in moderate to severe acne, along with mechanistic data, will be presented at the 2026 Fall Clinical Dermatology Conference, October 8–11. The trial was conducted by license partner Ascletis in China.

Why it matters — The presentation concerns denifanstat, which Ascletis develops as ASC40 in China under an exclusive license, while Sagimet develops it elsewhere.

FAQ

Frequently asked questions about SGMT stock

What is the SGMT stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Sagimet Biosciences, Inc. have a median 12-month price target of $27, with estimates ranging from $7 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SGMT stock a buy right now?

Of the 12 analysts covering Sagimet Biosciences, Inc., 11 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Sagimet Biosciences, Inc. 40 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SGMT?

As at 22 Oct 2026, Sagimet Biosciences, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (82 of 100).

Will SGMT stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +181.8% from the last close, and Ticker Nerd's factor model ranks Sagimet Biosciences, Inc. 40 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SGMT stock forecast for 2030?

No analyst covering Sagimet Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $56 over the next 12 months.

How has SGMT stock performed over the past year?

Sagimet Biosciences, Inc. returned +30.7% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sagimet Biosciences, Inc. do?

Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases.

What is the latest news on SGMT?

The most recent item we track (Zacks Investment Research, 23 Oct 2026): "Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet". Zacks Investment Research reported that the consensus price target for Sagimet Biosciences implies about 168.2% upside. It also noted that this metric has limited effectiveness, while upward earnings-estimate revisions may indicate near-term upside.

Company

About Sagimet Biosciences, Inc.

Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases. The company’s current programs center on fatty acid synthase (FASN) inhibitors and other drug candidates designed to address dysfunctional metabolic pathways and tissue fibrosis. Its lead assets include oral therapies under development for conditions such as metabolic dysfunction-associated steatohepatitis and related disorders, along with additional research programs in dermatology and oncology. Sagimet operates as a single business segment devoted to drug discovery, clinical development, and eventual commercialization of targeted therapies. The stock is used by investors to gain exposure to a specialty biotechnology company centered on in-house discovered, mechanism-based treatments for diseases with limited therapeutic options.

CEO Mr. David A. Happel · 16 employees · United States · https://www.sagimet.com